Dyax prices $60m offering; MacroGenics surges in first day of trading; Vivaldi acquires vaccine assets; and Rexahn licenses academic drug delivery platform.
Dyax stock sees small dip then gains as company prices $60m offering
BioNotebook: Dyax, MacroGenics, Vivaldi and Rexahn
Dyax prices $60m offering; MacroGenics surges in first day of trading; Vivaldi acquires vaccine assets; and Rexahn licenses academic drug delivery platform.